Actively Recruiting
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Led by University of Colorado, Denver · Updated on 2025-05-06
126
Participants Needed
1
Research Sites
225 weeks
Total Duration
On this page
Sponsors
U
University of Colorado, Denver
Lead Sponsor
W
Washington University School of Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.
CONDITIONS
Official Title
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 to 65 years of age
- Diagnosis of autosomal dominant polycystic kidney disease (ADPKD) based on the modified Pei-Ravine criteria
- Body-mass index of 27 kg/m2 or higher
- Estimated glomerular filtration rate of at least 30 mL/min/1.73m2
- Mayo Classification of C, D, or E from kidney ultrasound or MRI within the last 12 months
- Not currently in or planning to join any formal weight loss, physical activity program, or another interventional study
- Ability to provide informed consent
You will not qualify if you...
- Diagnosis of diabetes mellitus
- Current use or planned start of tolvaptan treatment
- Hospitalization or major surgery within the last 3 months
- Uncontrolled hypertension with systolic blood pressure over 160 or diastolic over 100 mm Hg
- Pregnancy, breastfeeding, or unwillingness to use effective birth control
- Regular use of medications affecting weight, appetite, food intake, or energy metabolism
- History of eating disorders such as anorexia nervosa, bulimia, or binge eating disorder
- Weight change over 5% in past 3 months except postpartum weight loss
- Inability to cooperate with or contraindication for MRI, including severe claustrophobia, implants, devices, or non-removable piercings
- History or presence of cancer within 5 years before screening
- Personal or family history of medullary thyroid carcinoma, thyroid nodules, or multiple endocrine neoplasia type 2
- Prior pancreatitis
- Weight 450 pounds or more
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Colorado - Anschutz Medical Campus
Aurora, Colorado, United States, 80045
Actively Recruiting
Research Team
K
Kristen Nowak, PhD, MPH
CONTACT
D
Diana George
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here